Votrient

Approved Uses

Votrient is a targeted therapy used for the treatment of specific types of cancer that have progressed or spread to other parts of the body. Its primary indications include:

• Advanced Renal Cell Carcinoma: This is a type of kidney cancer. Votrient is used when the cancer is in an advanced stage.
• Advanced Soft Tissue Sarcoma: This is a cancer that develops in the soft tissues of the body, such as muscles, fat, blood vessels, or nerves. Votrient is typically prescribed for patients with advanced soft tissue sarcoma who have already received chemotherapy treatment.

Limitations of Use

Votrient is not used to treat all forms of soft tissue cancer. It is specifically not indicated for the treatment of adipocytic soft tissue sarcoma or gastrointestinal stromal tumors. Healthcare providers determine if this medication is appropriate based on the specific subtype of the cancer and the patient's previous treatment history.

This medication works by interfering with the growth of new blood vessels that tumors need to grow and by blocking signals that tell cancer cells to multiply.

Mechanism of Action

Votrient belongs to a class of medications called kinase inhibitors. It works by interfering with the signals that tell cancer cells to grow and multiply.

The medication targets several specific proteins, known as tyrosine kinases, which are found on the surface of both healthy and cancerous cells. In some cancers, these proteins are overactive, leading to uncontrolled cell growth. Votrient helps block these signals to slow or stop the progression of the disease.

Inhibiting Tumor Growth

Votrient works in two main ways to combat cancer:

• Blocking cell division: By inhibiting specific growth factor receptors, the drug prevents cancer cells from receiving the signals they need to divide and spread.
• Stopping angiogenesis: Tumors require a dedicated blood supply to grow. Votrient blocks the vascular endothelial growth factor (VEGF) pathway, which prevents the tumor from forming new blood vessels. Without an adequate blood supply, the tumor cannot get the oxygen and nutrients it needs to survive and expand.

Because Votrient targets specific proteins involved in cell signaling, it is considered a targeted therapy. It is primarily used to treat advanced stages of certain cancers, such as renal cell carcinoma (kidney cancer) and soft tissue sarcoma.

Common Side Effects

Many people taking Votrient experience mild to moderate side effects. These may include:

• Diarrhea, nausea, or vomiting
• Stomach pain or loss of appetite
• Weight loss
• Changes in hair color
• Feeling tired or weak
• Headache
• Changes in the way food tastes

Serious Side Effects

Some side effects can be severe and require immediate medical attention. Contact a healthcare provider right away if you experience:

• Liver problems: Yellowing of the skin or eyes (jaundice), dark urine, or pain in the upper right side of the stomach.
• Heart issues: Chest pain, shortness of breath, swelling in the legs or ankles, or a fast or irregular heartbeat.
• High blood pressure: Severe headache, dizziness, or blurred vision.
• Bleeding or bruising: Unusual bleeding, nosebleeds, or coughing up blood.
• Blood clots: Sudden shortness of breath, chest pain, or swelling and pain in an arm or leg.
• Slow wound healing: Wounds that do not heal properly or old wounds that reopen.
• Thyroid problems: Feeling cold, constipation, or dry skin.
• Protein in the urine: Foamy urine or swelling in the face, hands, or feet.

Boxed Warning: Liver Toxicity

Votrient can cause severe and potentially fatal liver damage. Healthcare providers monitor liver function tests, including ALT, AST, and bilirubin levels, before starting treatment and at regular intervals during therapy. Treatment may need to be interrupted, reduced, or stopped if liver issues develop.

Cardiovascular Risks

• Heart Rhythm: This medication may cause QT prolongation and Torsades de Pointes, which are serious and potentially life-threatening heart rhythm disturbances.
• Heart Function: It may lead to heart failure or a decrease in the heart's ability to pump blood effectively.
• High Blood Pressure: Hypertension is common and can be severe. Blood pressure should be well-controlled before starting treatment and monitored closely thereafter.
• Blood Clots: There is an increased risk of arterial blood clots, which can lead to heart attack or stroke, as well as venous blood clots, such as pulmonary embolism.

Bleeding and Gastrointestinal Complications

Serious and sometimes fatal bleeding events have occurred in patients taking Votrient. The medication also increases the risk of developing a hole (perforation) or an abnormal connection (fistula) in the stomach or intestines.

Wound Healing

Votrient may interfere with the body's ability to heal wounds. It is typically discontinued at least one week before elective surgery and should not be restarted until at least two weeks after surgery and once the surgical site has adequately healed.

Pregnancy and Reproduction

This medication can cause harm to an unborn baby. Effective contraception is necessary for both males and females with reproductive potential during treatment and for a period after the final dose. Breastfeeding is not recommended during treatment and for at least two weeks after the last dose.

Additional Precautions

• Thyroid Function: Hypothyroidism may develop, requiring regular monitoring of thyroid-stimulating hormone (TSH) levels.
• Proteinuria: Protein in the urine may occur, which can be a sign of kidney issues. Monitoring through urinalysis is typically required.
• Neurological Effects: A rare condition called Posterior Reversible Encephalopathy Syndrome (PRES) has been reported. Symptoms may include headache, seizure, lethargy, confusion, or vision loss.

Pregnancy

Votrient can cause fetal harm when administered to a pregnant woman. Based on animal studies and its mechanism of action, this medication may lead to birth defects or pregnancy loss. It is important to inform a healthcare provider if you are pregnant or planning to become pregnant before starting this treatment.

Healthcare providers typically recommend the following precautions regarding pregnancy:

• Pregnancy Testing: Females of reproductive potential should have a pregnancy test to confirm they are not pregnant before starting Votrient.
• Contraception for Females: Use effective birth control during treatment and for at least 2 weeks after the final dose.
• Contraception for Males: Men with female partners who can become pregnant should use effective contraception during treatment and for at least 2 weeks after the final dose.

Breastfeeding

It is not known whether Votrient passes into human breast milk. Due to the risk of serious side effects in a nursing infant, breastfeeding is not recommended during treatment with Votrient and for at least 2 weeks after the last dose.

Dosage Forms

Votrient is supplied as a film-coated tablet intended for oral administration. The medication is designed to be swallowed whole and should not be crushed or broken.

• Oral Tablet: A film-coated tablet taken by mouth.

FDA Approval History

Votrient (pazopanib) was first approved by the U.S. Food and Drug Administration (FDA) in October 2009. Its initial approval was for the treatment of patients with advanced renal cell carcinoma, which is a form of kidney cancer.

In April 2012, the FDA expanded the approved use of Votrient to include the treatment of patients with advanced soft tissue sarcoma who have previously received chemotherapy. The FDA noted that the drug's effectiveness has not been established for patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors.

Boxed Warning

The FDA has issued a Boxed Warning for Votrient, which is the most serious type of warning required for prescription medications. This warning is due to the risk of hepatotoxicity, or severe liver injury, which can be fatal. Because of this risk, the FDA requires healthcare providers to perform liver function tests before starting the medication and to continue monitoring liver health throughout the course of treatment.

Regulatory Status and Monitoring

Votrient is a prescription-only medication. In addition to liver monitoring, the FDA-approved labeling includes warnings regarding other serious risks that require clinical oversight, such as:

• High blood pressure (hypertension)
• Heart rhythm changes (QT prolongation)
• Heart failure or decreased heart pumping function
• Severe bleeding events
• Perforations or tears in the stomach or intestines
• Thyroid dysfunction

Regulatory authorities continue to monitor the safety of Votrient through post-marketing surveillance and clinical trials investigating its use in different patient populations, including pediatric bone cancer research.

Factors Affecting Cost

Several factors can influence the total price of Votrient treatment:

• Insurance Coverage: Your out-of-pocket expenses, such as copays or coinsurance, are determined by your specific health insurance plan. Some insurance providers may require prior authorization before they agree to cover the cost of the medication.
• Pharmacy Choice: Prices may differ between local retail pharmacies, mail-order pharmacies, and specialty pharmacies.
• Generic Availability: Pazopanib is the generic version of Votrient. Generic medications are generally less expensive than brand-name versions while providing the same therapeutic effect.

Financial Assistance

If you have difficulty affording Votrient, there may be resources available to help manage the cost:

• Patient Assistance Programs: Drug manufacturers sometimes offer programs to provide medications at a lower cost or for free to individuals who meet specific financial criteria or lack insurance.
• Copay Savings Cards: Patients with commercial insurance may be eligible for savings cards that reduce the amount paid at the pharmacy.

To understand your specific costs, it is best to contact your insurance provider or speak with your pharmacist. They can provide information on your plan's formulary and any available financial support options.